What changed in Vaxcyte, Inc.'s latest annual report
In the year ended 31 Dec 2025, Vaxcyte, Inc.'s cash and cash equivalents fell 55.2% to USD 173.96m, from USD 387.88m; total liabilities rose 54.4% to USD 317.21m, from USD 205.50m; shareholders' equity fell 18.8% to USD 2.69bn, from USD 3.31bn.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 387.88m to USD 173.96m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Net income | -463.93m | -766.63m | Not comparable |
| Total assets | 3.51bn | 3.00bn | Down 14.5% |
| Total liabilities | 205.50m | 317.21m | Up 54.4% |
| Cash and cash equivalents | 387.88m | 173.96m | Down 55.2% |
| Shareholders' equity | 3.31bn | 2.69bn | Down 18.8% |
Questions people ask
Is Vaxcyte, Inc. profitable?
Not in its latest year: it reported a net loss of USD 766.63m in the year ended 31 Dec 2025. The year before: a net loss of USD 463.93m.
How much cash and debt does Vaxcyte, Inc. have?
At its latest year end (31 Dec 2025), Vaxcyte, Inc. reported cash and cash equivalents of USD 173.96m.
Where do these numbers come from?
From Vaxcyte, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Vaxcyte, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%